4.1 Editorial Material

A case of recurring acute exudative polymorphous vitelliform maculopathy successfully treated with intravitreal Ozurdex injection

Journal

EUROPEAN JOURNAL OF OPHTHALMOLOGY
Volume -, Issue -, Pages -

Publisher

SAGE PUBLICATIONS LTD
DOI: 10.1177/11206721231178559

Keywords

AEPVM; CMO; intravitreal dexamethasone implant; corticosteroid; Ozurdex((R))~

Categories

Ask authors/readers for more resources

We report the recurrence of acute exudative polymorphous vitelliform maculopathy (AEPVM) in a case that was successfully treated with intravitreal corticosteroid. The patient showed improved retinal and retinal pigment epithelium (RPE) function and good visual outcome. This case highlights the effectiveness of Ozurdex((R)) in managing recurrent AEPVM.
Introduction: We describe a case of acute exudative polymorphous vitelliform maculopathy (AEPVM) that recurred 9 years after the initial event. To the best of our knowledge, this is the first report of recurrent AEPVM showing recovery of retinal and retinal pigment epithelium (RPE) function and good visual outcome following treatment with intravitreal corticosteroid. Case description: A 45-year-old Caucasian woman first presented with AEVPM in 2009. Her condition spontaneously resolved and she remained stable over several years. 9 years later, her condition recurred with bilateral reduction in visual acuity. Fundus examination revealed multiple small yellowish subretinal lesions across the posterior pole in both eyes. Optical coherence tomography (OCT) showed bilateral cystoid macular oedema (CMO). She was referred for electrophysiology and her electrooculogram findings were in keeping with severe generalised RPE dysfunction bilaterally, with a light peak to dark trough ratio (Arden index) of 110%, comparable to her initial presentation 9 years earlier. She was initially treated with oral steroids with some improvement. However, the maculopathy in the left eye recurred on cessation of oral treatment. A sustained-release 700ug dexamethasone intravitreal implant (Ozurdex((R))) was inserted in the left eye to which she responded remarkably, with improvement in visual acuity and complete resolution of the CMO. A year later, at her most recent clinic visit in March 2021, there was no evidence of any further recurrence. Conclusion:Our case demonstrates clinical and imaging findings consistent with recurrence of AEPVM with CMO that has been successfully treated with Ozurdex((R)).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available